Zapata Quantum CEO Sumit Kapur will lead a fireside chat on June 17th at the Benchmark/StoneX Quantum Computing Summit in Washington D.C., focusing on the critical role of software in realizing the potential of quantum technology. This announcement follows the company’s recognition for recent advancements; a study developed in collaboration with Dana-Farber Cancer Institute, the University of Toronto and Insilico Medicine was named one of Nature Biotechnology’s Top 10 Papers of the year and featured on the journal’s December cover. Beyond drug discovery, Zapata’s work is attracting attention across diverse sectors, as demonstrated by a panel discussion on June 26th at Quantum.Tech World in Boston featuring leaders from Verizon, Nestlé, and the UK Financial Conduct Authority. This convergence of industries suggests a broadening scope for quantum computing applications, extending beyond traditional scientific boundaries.
Zapata Quantum at Industry and Investor Conferences
On June 17th at 10:40 a.m., Kapur will discuss the increasingly vital role of software in unlocking the potential of quantum hardware. This focus on application development is noteworthy given the historical emphasis on hardware advancements in the quantum field, and reflects an industry seeking demonstrable value. Kapur will also be available for one-on-one meetings with institutional investors at the Westin Georgetown, with scheduling coordinated through Benchmark/StoneX or Alliance Advisors Investor Relations at investors@zapataquantum.com. Recognition from Nature Biotechnology further underscores Zapata’s progress; a study led by the company was named among the journal’s Top 10 Papers of the year and prominently featured on the December cover. Zapata will showcase this work, and Kapur will deliver a keynote on it, at Quantum.Tech World in Boston on June 26th.
The intersection of quantum computing with diverse fields is also a key theme for Zapata; Dr. Jonathan Olson will discuss the relationship between quantum computing, artificial intelligence, and high-performance computing. Attendees can also meet with Zapata and demo its Quantum Application Intelligence platform in the conference exhibition, indicating a focus on practical demonstrations alongside theoretical discussions and solidifying the company’s position as a provider of quantum solutions.
Quantum Application Intelligence Platform for Drug Discovery
Zapata Quantum is shifting the focus of quantum computing from hardware limitations toward practical software applications, particularly within the pharmaceutical industry. This emphasis is evident in the company’s upcoming presentations and collaborative research, signaling a maturation of the field beyond theoretical potential and into demonstrable results. This achievement represents a step forward in leveraging quantum computing for drug discovery, potentially accelerating the identification of novel therapeutic candidates. Sumit Kapur, CEO of Zapata Quantum, will detail this progress during a keynote address at Quantum.Tech World in Boston on June 26th, specifically focusing on the findings published in Nature Biotechnology. The company’s Quantum Application Intelligence platform is central to this work, offering a means to translate quantum algorithms into solutions for real-world challenges. This combination of industries underscores the wide range of potential applications being considered for quantum technologies.
Zapata’s participation in a session at a16z Tech Week Boston on May 27th demonstrates an effort to connect quantum innovation with capital allocation, suggesting growing investor interest in the field. The company’s platform, supported by a portfolio of over 60 granted and pending patents, aims to accelerate the development of quantum applications across multiple sectors, including defense and materials discovery.
Attendees can also meet with Zapata and demo its Quantum Application Intelligence TM platform in the conference exhibition.
